Equities

AZTR

US05479L1044

Market Closed - Nyse Other stock markets 01:40:00 28/06/2024 am IST			5-day change	1st Jan Change
0.132 ^USD	+12.72%		-7.30%	-85.65%

16/06	Certain Options of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2024.	CI
16/06	Certain Warrants of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2024.	CI

Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

July 11, 2023

Azitra, Inc. announced the appointment of Travis Whitfill as Chief Operating Officer. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. Whitfill is a biotech leader and entrepreneur.

He cofounded Azitra in 2014 and has served on the company's board of directors since 2014. Previously, he was a partner at Bios Partners, a biotechnology-focused venture capital firm, for nine years.

Latest news about AZITRAPAR

Certain Options of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2024.	16/06	CI
Certain Warrants of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2024.	16/06	CI
Certain Common Stock of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2024.	16/06	CI
Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting	10/05	CI
Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting	23/04	CI
Azitra, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/03	CI
Azitra Closes $5 Million Public Offering	17/02	MT
Top Midday Decliners	15/02	MT
Azitra Prices Stock Offering at $0.30 a Share	14/02	MT
Azitra Launches Common Stock Offering; Shares Drop	19/01	MT
Certain Warrants of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2023.	16/12	CI
Certain Options of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2023.	16/12	CI
Certain Common Stock of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2023.	16/12	CI
Earnings Flash (AZTR) AZITRA Posts Q3 Revenue $310,700	15/11	MT
Azitra, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	15/11	CI
Azitra, Inc.(NYSEAM:AZTR) added to S&P TMI Index	18/23/18	CI
Earnings Flash (AZTR) AZITRA Reports Q2 Revenue $172,000	15/23/15	MT
Azitra Adds Barbara Ryan and John Schroer to Its Board of Directors	20/23/20	CI
Azitra Names Travis Whitfill as Chief Operating Officer	12/23/12	MT
Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer	11/23/11	CI
Top Premarket Decliners	06/23/06	MT
Insider Buy: Azitra	26/23/26	MT
Insider Buy: Azitra	26/23/26	MT
Azitra Closes IPO, Raises $7.5 Million Gross Proceeds	22/23/22	MT

Chart AZITRAPAR

Duration

Period

More charts

Company Profile

Azitra, Inc. is an early-stage clinical biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. The Companyâs product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.

Sector

More about the company